# Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

> **NCT04885634** · PHASE3 · WITHDRAWN · sponsor: **Axel Brandes**

## Conditions studied

- Atrial Fibrillation
- Overweight and Obesity

## Interventions

- **DRUG:** Semaglutide Injectable Product
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04885634
- **Lead sponsor:** Axel Brandes
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10
- **Primary completion:** 2024-01
- **Final completion:** 2024-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Not received funding.
- **Last updated:** 2023-11-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04885634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04885634, "Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04885634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*